Journal
PSYCHOPHARMACOLOGY
Volume 162, Issue 1, Pages 37-41Publisher
SPRINGER
DOI: 10.1007/s00213-002-1083-5
Keywords
PET; D-2 receptor; striatum; limbic system; sertindole
Categories
Ask authors/readers for more resources
Rationale: Sertindole is a new atypical antipsychotic drug. Preclinical pharmacology suggests that sertindole has a preferential effect on the activity of limbic and cortical dopaminergic neurons. Clinical trials have shown antipsychotic efficacy and very few extrapyramidal symptoms (EPS) with sertindole at 20 mg/day. Objectives: This positron emission tomography (PET) study aimed to measure D-2 receptor occupancy in striatal and extra-striatal regions induced by clinically representative doses of sertindole in patients with schizophrenia. Method: Four stabilized schizophrenic out-patients received sertindole 20 mg/day for 6-8 weeks. PET was performed using [C-11]raclopride to measure D-2 receptor occupancy in the striatum and [C-11]FLB457 to measure occupancy in the neocortex and thalamus, i.e. regions with very low D-2 receptor density. Results: Striatal D-2 receptor occupancy was 52-68%. Similar occupancies were found in the thalamus, and the temporal and frontal cortices. Conclusions: Sertindole appears efficacious at a low D-2 receptor occupancy, comparable to that produced by clozapine. This finding could explain the low risk of EPS. The functional limbic selectivity of sertindole was not reflected in regional differences in receptor occupancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available